348 results about "Complex formation" patented technology

A composition of an ultrasound coupling medium is provided. The composition comprises at least 90% water, at least one preservative, and at least one base substance, wherein the composition is extensible into a film with a thickness of up to 1/10 mm, wherein the composition can withstand a pressure of up to 30 kp without tearing, wherein the composition can adapt exactly to skin surface without causing any significant air pockets, and wherein the composition can be removed from skin with substantially no residue left behind. The at least one base substance may be a galactomannan, a polyvinyl alcohol (PVA), a complex formation of galactomannan and borate ions, or comninations thereof.

An electrode composite and to its manufacturing process. The composite includes an active element, i.e. one exhibiting electrochemical activity, a conductive additive and a binder. The conductive additive is a mixture of conductive additives containing at least carbon nanofibres (CNFs) and at least carbon nanotubes (CNTs). Also, the negative electrodes for electrochemical devices of the lithium battery type including said composite and to the secondary (Li-ion) batteries provided with such a negative electrode.

The invention provides a compound tunnel shield suitable for construction of complex formation, relating to an architectural construction machinery. The compound tunnel shield comprises a compound cutter head suitable for construction of soft soil formation, hard rock formation, formation with uneven hardness and compound formation with both soft soil and hard rock; 3 excavation modes adopting an open mode, a local atmospheric pressure mode or an excavated surface stabilization mode of an earth pressure balance mode according to different geological characteristics of the geology, and a ground conditioning system; the cutter head is respectively provided with a soft soil layer construction tool and a hard rock layer construction tool, cutters are changed to adapt to different formations in the process of the construction thereof; addition agent is injected into the cutter head surface, a soil chamber or a screw conveyer and the addition agent and muck are mixed by rotary stirring of the cutter head, the soil chamber or the screw conveyer to adapt to different formations through ground conditioning. The invention solves the problem of safe construction of the tunnel shield in soft soil, decomposed rock, formations with uneven hardness, sand layer and sand gravel formation, etc.

The invention discloses a Non-Equilibrium Capillary Electrophoresis of Equilibrium Mixtures (NECEEM) method and NECEEM-based practical applications. The NECEEM method is a homogeneous technique, which, in contrast to heterogeneous methods, does not require affixing molecules to a solid substrate. The method of the invention facilitates 3 practical applications. In the first application, the method allows the finding of kinetic and thermodynamic parameters of complex formation. It advantageously allows for revealing two parameters, the equilibrium dissociation constant, K_d, and the monomolecular rate constant of complex decay, k_off, in a single experiment. In the second practical application, the method of this invention provides an approach for quantitative affinity analysis of target molecules. It advantageously allows for the use of affinity probes with relatively high values of k_off. In the third practical application, the method of this invention presents a new and powerful approach to select target-binding molecules (ligands) from complex mixtures. Unique capabilities of the method in its third application include but not limited to: (a) the selection of ligands with pre-determined ranges of kinetic and thermodynamic parameters of target-ligand interactions, (b) the selection of ligands present in minute amounts in complex mixtures of biological or synthetic compounds such as combinatorial libraries of oligonucleotides, and (c) the selection of ligands for targets available in very low amounts. In particular, the method of this invention provides a novel approach for the selection of oligonucleotide aptamers. The NECEEM-based method can be used for discovery and characterization of drug candidates and the development of new diagnostic methods.

A rigid shaped product is produced from organic or inorganic solid particulate materials, preferably waste materials by mixing the solid particulate materials with a non-toxic composed of an aqueous dispersion of a blend of acrylic and polyurethane resin which forms a self-crosslinking composition resin material in a thermoplastic state to form a flowable mixture. The flowable mixture is then formed into a desired shape such as a flat panel or sheet, by molding, extrusion, or injection molding, and cured to thermoset the resin material and form a rigid, shaped product such as a construction board.

The present invention relates to methods for identifying analytes in a sample comprising the steps of: (a) incubating said analytes with a plurality of bipartite capture probes, said capture probes being immobilized in predefined regions on a solid substrate, and each capture probe consisting essentially of a first fragment which is at one end immobilized to said substrate and at the other end is complementary linked to a second fragment, wherein said second fragment comprises an extension fragment capable of identifying an analyte; (b) monitoring complex formation between sample analytes and extension fragments; (c) sequentially modifying complex formation conditions; allowing the release of captured analyte molecules from the substrate; and (d) detecting and identifying the released analytes. The present invention also relates to different uses of said methods as well as microarrays and kits for performing said methods.

The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed.

Woven preforms, for example those used for jet aircraft engine fancases, may need additional stiffeners to improve the strength and/or dynamic performance of the preform assembly, as well as to serve as attachment points. The present invention describes several improved woven preforms that include circumferential or axial stiffeners, as well as methods of manufacturing the same. One embodiment includes circumferential stiffeners added to a woven preform. Another embodiment includes sub-preforms with integral flanges that combine to make integral stiffeners. A further embodiment includes an intermediate stiffener wrapped onto a base sub-preform wrap, wherein the intermediate stiffener wrap incorporates intermediate stiffeners. Another embodiment incorporates bifurcations in one or more layers of an outermost wrap of a multi-layer fabric composite that forms a preform, wherein the bifurcated outer wrap is folded to form stiffeners that may be oriented circumferentially or axially.

A method for multipath imaging of three-dimensional volumes of seismic data, given the subsurface velocity distribution. Ray tracing is used to generate the volumes of information needed for migration, but using coarse-scaled grids for computational efficiency. Interpolation methods are disclosed that address the specific shot points and receiver locations and that enable a final image on a grid with the desired resolution. Data storage and retrieval techniques are also disclosed.

Provided are methods and systems for detecting formation of nucleotide-specific ternary complexes comprising a DNA polymerase, a nucleic acid, and a nucleotide complementary to the templated base of the primed template nucleic acid. The methods and systems facilitate determination of the next correct nucleotide without requiring chemical incorporation of the nucleotide into the primer. These results can even be achieved in procedures employing unlabeled, native nucleotides.

The present invention provides compositions, formulations and methods providing for the effective dissolution of inorganic fluorides in solvents via incorporation of a dissociating agent component. Dissociating agents of the present invention participate in chemical reactions in solution, such as complex formation, acid-base reactions, and adduct formation reactions, that result in enhancement in the dissolution of inorganic fluorides in a range of solvent environments. Dissociating agents comprising Lewis acids, Lewis bases, anion receptors, cation receptors or combinations thereof are provided that significantly increase the extent of dissolution of a range of inorganic fluorides, particularly inorganic fluorides, such as LiF, that are highly insoluble in many solvents in the absence of the dissociating agents of the present invention.

Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.

A method is described for altering the properties such as the accumulation, the stability and/or integrity, the subcellular localisation, the post-translational modifications, the ability to get purified, and the phase partitioning behaviour of natural or recombinant target proteins expressed in a host organism. The method involves the co-expression of natural or recombinant proteins along with a specific binding partner that sequesters the target recombinant protein into a complex. The binding partner is supplied as a separate protein allowing formation of intermolecular complexes or is fused to the protein of interest, allowing the formation of intramolecular complexes. The binding partner can also be used to alter the subcellular localisation without modifying the sequence or structure of the target protein itself. This can be achieved by either incorporating appropriate targeting signals into the binding ligand, which are then linked to the target protein through complex formation, or complex formation itself may alter the subcellular localisation. The same strategy can be used to provide an affinity tag to facilitate protein purification. The principle of the invention is demonstrated by the coexpression of an unstable antibody and its cognate antigen.